Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

Research by the authors on CHIKV is supported by NIH grants AI069145, AI082202, AI093491 and by a grant from the National Institute of Allergy and Infectious Disease (NIAID) through the Western ...

Chikungunya is a disease that is caused by the chikungunya virus which is transmitted to humans by infected mosquitoes. Its name is derived from a word in the Makonde language that means contorted or ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...

You will be redirected to our submission process. Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that has emerged in recent years as a major human pathogen. CHIKV causes major ...

Valneva SE VALN, a specialty vaccine company, recently reported positive Phase 3 - VLA1553-321 data in adolescents (12 to 17 ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva's single-shot chikungunya (CHIKV) vaccine, IXCHIQ (Chikungunya Vaccine, Live), has demonstrated positive phase 2 data among children, according to a recent announcement from the company. 1,2 ...

Therefore a rapid, specific and sensitive test is necessary for effective surveillance of new CHIKV circulating strains. Moreover, no quantitative molecular tool has been described to study CHIKV ...

CHIKV-VLP is under clinical development by Bavarian Nordic and currently in Pre-Registration for Chikungunya Fever. According to GlobalData, Pre-Registration drugs for Chikungunya Fever have a 100% ...

Dan has generated infection models for Zika virus, chikungunya virus (CHIKV) and Mayaro virus (MAYV) to characterize alphavirus infection and define the immune responses to the virus infection.

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...